|
|
Speakers 
Zami Aberman,
President and Chief Executive Officer,
Pluristem Life Systems Inc
|
 Dr Simon Bennett,
Business Development Director,
Glide Pharma
|
Hans Bostrom,
Director, Scientific Liaison,
Merck, Sharp and Dohme
|
 Mr Tony Bradshaw,
Director bioProcessUK,
BioIndustry Association
Tony has a PhD in Life Sciences from Heriot Watt University, Edinburgh. He has been involved in Biotechnology Business Development for 16 years working for British Sugar, University College London and in executive search for Ruston Poole and Harvey Nash. He was appointed to the Board of UK BioIndustry Association for the period 1999-2001.
He has been involved in bioprocessing since 1994. From 1994 -1999 he was Director of Business Development for University College London’s Advanced Centre for Biochemical Engineering. He developed the industrial collaboration strategy at UCL which involved setting up an industrial training programme (MBI Training) which attracted over 500 people from 100 companies across the world.
He is the Director of bioProcessUK, a Knowledge Transfer Network funded through the DTI Technology Programme, and managed by the BioIndustry Association. It is dedicated to the advancement of the bioprocessing sector in the UK.
|
 Dr Crawford Brown,
Chief Executive Officer,
Eden Biodesign
Crawford is CEO of Eden Biodesign (contract development and manufacturing services) and leads Eden Biopharm consulting services now established one of Europe’s largest and most successful specialist biopharmaceutical technical-regulatory consultancies.
In 2004 Eden raised £5m equity capital from an investment syndicate led by Stephens Inc, the largest privately held investment banking firm outside of Wall Street. Additionally, Eden successfully won the European-wide UK government tender to lease and operate the UK National Biomanufacturing Centre a £30 million project sponsored by the North West Development Agency, the European Regional Development Fund and the UK Department of Trade and Industry.
Crawford has been involved with the Biotech sector for over 20 years having held senior positions in product development at Celltech-Medeva Pharma (Liverpool), British Biotech (Oxford) and Wellcome Biotech (Beckenham, Kent). At Medeva, as Director of Product Development, he established one of the UK’s largest product development teams that were the first in the UK to take a recombinant vaccine from the laboratory through to approval by the European Medicines Control Agency (EMEA).
Crawford qualified from Strathclyde University with a BSc in Applied Microbiology and a PhD in Chemical and Process Engineering. He is a Senior Visiting Lecturer on Modular Training for the Bioprocess Industries (MBI) course at the Advanced Centre for Biochemical Engineering. University College, London.
Crawford has completed assignments over the past five years in Denmark, Germany, Switzerland, Netherlands, Australia, India, Japan, South Korea, Taiwan and the USA. The focus of assignments is exclusively biopharmaceutical development including therapeutic and prophylactic vaccines, monoclonal antibodies, gene therapy and stem cell/tissue engineered products.
|
Nigel Burns,
Independent Advisor,
Independent Advisor
Nigel Burns currently acts as an advisor to companies, venture capitalists and governments, calling on his 20 years of experience in many aspects of the biotechnology industry. He spent 9 years as part of the senior management team at Cambridge Antibody Technology (CAT) having joined in 1997 as Vice President Pre-Clinical Development and being promoted to Senior Vice President in October 2000. During 2004 he assumed responsibility for the management of CAT’s strategic discovery and development alliances. Previously, Nigel was with British Biotech (now part of Vernalis) where he headed the Process Technology Division and played a significant role in developing its biotechnology-based products. Prior to this, he held scholarships at the Central Drug Research Institute, Lucknow, India and at the California Institute of Technology. He hold a PhD from King’s College London.
|
Dr Luis Carrasqueiro,
Business Development Manager,
UCL Business
|
Duncan Casson,
Chief Operating Officer,
PanGenetics
|
 David Colpman,
Senior Vice President of Business Development,
Shire Pharmaceuticals
|
 Dr Jonathan Dando,
Managing Director,
Dando and Colucci LLC
Jonathan Dando PhD, has worked for Sandoz (Vienna, Austria), Systemix (Palo Alto, U.S.A.), the Telethon institute for Gene Therapy (Milan, Italy) INSERM (Villejuif, France) and INSERM Transfert (Paris, France) where he was Director of the International Projects Department (staff of 20, managing over 20 projects with total costs in excess of 500 million €). He has sat on the Executive Committee of three international consortium focusing on Stem cells and Tissue engineering, antimicrobials and neurotransmitters as well as a member of the board of directors for the Marie Curie Fellowship Association. Dr. Dando is a co-founder of Dando and Colucci LLC and works in Rome, on site with the Fondazione Parco Biomedico San Raffaele addressing their business development and international partnering strategies.
|
 Dr Aleksandar Danilovski,
Senior Director of Vertical Integration,
Pliva
|
 William Downey,
Managing Director,
HighTech Business Decisions
Mr. Downey is president and managing director of HighTech Business Decisions, a consulting company that specializes in market research for business-to-business biotechnology, pharmaceutical manufacturing, medical and electronic products. Mr. Downey has over 25 years of experience and held various positions in marketing, sales, strategy and finance. Mr. Downey has a Masters in Business Administration form Washington University in St. Louis and Bachelors from the University of Michigan in Ann Arbor.
|
 Dr Dinesh Dua,
President, International and Biotechnology Strategic Un,
Wockhardt
Dinesh Dua, is the President of Wockhardt Ltd’s International & Biotechnology Strategic Business Unit( SBU).
Mr Dua holds a Masters in Business Management (M.B.A.)-1979 batch from the Indian Institute of Management Ahmedabad. He has over 27 years of professional experience across varied industries such as Healthcare and Pharmaceuticals, Petrochemicals and Consumer goods, having worked in multinational organizations such as Hoechst (Sanofi Aventis) & Berger Paints, and large Indian Corporates like Reliance & Jubilant Organosys. His last assignment was as President at Zydus Cadila Healthcare.
He has also served as a member of various subcommittees of the Confederation of Indian Industry (CII), one of the major Industry Associations of India.He is also a visiting faculty to leading & reputed Management institutes in India.
|
 Mr Fuad El-Hibri,
Chief Executive Officer and Chairman,
Emergent BioSolutions Inc.
Mr. El-Hibri has served as chief executive officer and as chairman of the board of directors of Emergent BioSolutions since June 2004 and as president since March 2006. Mr. El-Hibri served as chief executive officer and chairman of the board of directors of BioPort Corporation from May 1998 until June 2004, when, as a result of a corporate reorganization, BioPort became a wholly owned subsidiary of Emergent. The Company subsequently renamed BioPort as Emergent BioDefense Operations Lansing Inc. Mr. El-Hibri served as chairman of Digicel Holdings, Ltd., a privately held telecommunications firm, from August 2000 to October 2006. He served as president of Digicel from August 2000 to February 2005. Mr. El-Hibri has served as chairman of East West Resources Corporation, a venture capital and financial consulting firm, since June 1990. He served as president of East West Resources from September 1990 to January 2004. Mr. El-Hibri is a member of the board of trustees of American University and a member of the board of directors of the International Biomedical Research Alliance, an academic joint venture among the NIH, Oxford University and Cambridge University. He also serves as chairman and treasurer of El-Hibri Charitable Foundation. Mr. El-Hibri received a master's degree in public and private management from Yale University and a B.A. in economics from Stanford University.
|
 Dr Ronald Ellis,
Senior Vice President, Research and Development,
Avant Immunotherapeutics
Dr. Ronald Ellis has 25 years of industry experience in research and development of vaccines and biologics. He has championed or led R&D efforts on a wide range of viral and bacterial vaccines from discovery or in-licensure through early and advanced development as well as to product licensure and launch – including several vaccines on the market – those for human papilloma virus, rotavirus, varicella, hepatitis B, and Haemophilus influenzae type b. He is Editor-in-Chief of the peer-reviewed journal Human Vaccines, launched in 2005.
|
 Dr Brendan Fish,
Director, Bioprocess Sciences,
Cambridge Antibody Technology
(1998-Present) Cambridge Antibody Technology. Joined CAT as Head of Downstream Processing in November 1998 and was promoted to Director in October 2001. Assumed responsibility for all of Bioprocess Sciencen in sping 2004. Currently in control of all aspects of the development of purification methodologies, formulation and delivery solutions and biochemical and biophysical characterisation of all CAT’s products in relation to their use in commercial pharmaceutical processes. This includes process design and optimisation, formulation and stability studies, comparability and product characterisation, scale-up, process cost modelling, process integration and technology transfer to GMP Production for clinical trial supply.
(1991-1998) Delta Biotechnology Limited. Consulting Scientist. Played a key role in the development of Delta’s biotechnology-based products providing expert opinion and strategies for QA, QC, Production, Marketing, Operations, Regulatory Affairs and Engineering on all aspects of Process Development.
(1989-1991) University of Toronto in Canada. Post-doctoral fellowship working in the School of Nutritional Sciences, studying the anti-nutritional effects of lectins in the diet.
Also held posts as a Reseach Assistant and a Medical Laboratory Scientific Officer.
|
 Dr Lallan Giri,
Vice President, Scientific Affairs,
Emergent BioSolutions Inc.
Currently Vice President of Scientific Affairs. Manages scientific and technology aspects in the commercial development of vaccines, evaluation and in-licensing of technology, partnership, and merger and acquisition.
Formerly he was responsible for Research and Development, Regulatory Affairs, and Quality Operations at BioPort Corporation, Lansing, Michigan site. He led a team at the Bioport Coporation, Lansing, Michigan to the successful approval of the Anthrax vaccine manufacturing facility and BLA. Before joining BioPort Corporation in 2000 he held the position of Executive Director of Quality Operations and Regulatory Affairs (1993 -1999) at the Glaxo Wellcome Biopharmaceutical Inc (GWBI) and was responsible for getting the GWBI approved by FDA for the manufacture and distribution of a – interferon (Wellferon™) for Hepatitis C indication. He also held the position of Director of Analytical Development and Quality Control at the Aventis Pasteur
( formerly Pasteur Merieux Connaught ), in the US (1989-1993). While in this position played a key role in the development and licensing of five vaccines for adult and pediatric indications.
|
Dr Tim Hammond,
Technology Transfer Manager,
Durham University
|
Dr Stephen Hart,
Chief Scientific Officer,
Genex Biosystems Ltd
|
 Tony Hickson,
Head of Bioscience,
Imperial Innovations
Tony Hickson joined Imperial Innovations in early 2002 and is Head of the Bioscience Team. Tony has fifteen years of varied commercial experience in bioscience companies including Wellcome, Murex Biotech (which was aquired by Abbott Laboratories) and Kalibrant Ltd..
|
 Tom Hockaday,
Managing Director,
Isis Innovation
Tom Hockaday is the Managing Director of Isis Innovation Ltd, the technology transfer company of the University of Oxford. Tom joined Isis in March 2000, following seven years in technology transfer at Bristol University, where he was Managing Director of Bristol Innovations Ltd, and four years at University College London. Tom was Chairman of UNICO in 2003, the UK’s university technology transfer association. Isis provides Oxford University researchers with commercial advice on patenting and licensing, spin-out company formation and managing consulting and services contracts (Isis has concluded over 250 licence agreements, 150 consulting agreements, and assisted in the formation of 49 spin-out companies since 1997). Isis manages the University proof of concept and seed fund; works with the local NHS Hospital Trust to support their technology transfer activities; and in 2004 set up a division to provide consulting expertise on technology transfer to universities, research institutes and governments outside Oxford. www.isis-innovation.com
|
 Dr Chris Holloway,
Group Director of Regulatory Affairs,
ERA Consulting und Pharmaberatungs GmbH
Chris Holloway, Ph.D., Dr.rer.hum.biol.habil., is Group Director of Regulatory Affairs at ERA Consulting, with overall responsibility for the company’s operations in Germany, London, Washington, DC, and Australia. He has worked in regulatory affairs, specializing in biotech products and other biologics, for more than 15 years, since leaving academia where he was Professor of Clinical Biochemistry at Hannover Medical School in Germany. Chris graduated in 1971 and obtained his Ph.D. in 1975, after which he held a Royal Society European Research Fellowship at the Max-Planck-Institute in Germany. He then moved into university, and was awarded the venia legendi in 1982. Chris is particularly interested in regulatory strategies for novel biological therapeutics, interacting wherever possible with regulators to define expedient routes towards marketing authorizations. He has worked on more than 200 different products, contributing particularly towards approaches to manufacturing and control as well as early non-clinical and clinical development. His team has compiled dossiers, and Chris authors expert reports for European submissions. With his scientific background in the field of protein biochemistry and physiological chemistry, Chris has an active interest in concepts of comparability, when production processes are scaled-up or changed. He has been a regular speaker at conferences on this subject.
|
 Karen Huebscher,
Global Head of Business Development and Licensing,
Novartis Vaccines and Diagnostics
Karen Huebscher is Head, Business Development & Licensing (BD&L) for Novartis Vaccines & Diagnostics. In this role, her team identifies collaboration agreements such as in-licensing, out-licensing or acquisitions that will position Novartis Vaccines & Diagnostics the division for future success. Previously, she was Global Head of Investor Relations, Novartis International AG. In that role, she was responsible for running the Group’s Investor Relations Department with teams in both New York and Basle. She brings with her seven years’ experience in molecular biology research both in industry and in academia in the UK and Switzerland.
|
 Dr Avinoam Kadouri,
Chief Executive Officer,
Rainbow Biotechnologies
|
 Dr Frank Kalkbrenner,
Vice President, Research and Development Licensing and Information Management,
Boehringer Ingelheim
Dr. Kalkbrenner studied medicine from 1980 to 1987 and holds a degree in Pharmacology and Toxicology. His Ph.D. thesis focussed on the regulation of the prostaglandin H synthase. As postdoctoral research fellow at the Max-Planck Institute for Molecular Genetics he worked in the field of gene regulation. Later as research scientist in the Institute of Pharmacology in Berlin he studied G-protein mediated signal transduction and ion channels. In the year 1997 he joint Schering AG and worked for 3 years as senior scientist in experimental dermatology. In 1999 he moved to Boehringer Ingelheim and held for 6 years positions in the department of pulmonary research first as senior scientist and later as director. In 2005 he took over the responsibility for the licensing department. Since the beginning of 2006 he is holding the position of a Vice President for Licensing and Information Management. In this function he is responsible for the licensing activities in the German Boehringer Ingelheim organization as well as for competitive assessment, scientific data bases and the scientific library. Dr. Kalkbrenner authored more than 30 peer reviewed scientific publications and book chapters.
|
Dr Hermann Katinger,
Chief Executive Officer,
POLYMUN Scientific Immunobiologische Forschung GmbH
|
 David Kerr,
Chief Medical Officer,
ClinOx
Professor David Kerr is Rhodes Professor of Clinical Pharmacology and Cancer Therapeutics at the Department of Clinical Pharmacology, University of Oxford. He is working with colleagues in Oxford to build a new Institute for Cancer Medicine. He has an international reputation for treatment for and research into colorectal cancer, and he is developing new approaches to cancer treatment which involve gene therapy. The quality of his work has been recognised by the award of several international prizes and the first NHS Nye-Bevan award for innovation. He has published more than 350 articles in peer-reviewed journals and has contributed to many books on cancer. Professor Kerr has chaired the Advisory Board developing a vision for the future of Scotland’s Health Service and produced a 20 year plan for the future of the NHS in Scotland, Editor-in-Chief of Annals of Oncology, Europe’s premier medical oncology journal, and is on the editorial broad of several other journals including Nature Clinical Practice Oncology. He was elected Fellow of he Academy of Medical Sciences in 2000 and appointed Commander of the British Empire in 2002.
|
 Mr David Lawrence,
CFO,
Acambis
David was appointed to the Board on 8 July 2004 and officially joined Acambis in August of that year.
Prior to joining Acambis, David was Vice President of Finance for Chiron Vaccines, part of Chiron Corporation, where he was responsible for strategic planning, business development, mergers and acquisitions, and played a lead role in Chiron’s acquisition of the UK vaccine company, PowderJect Pharmaceuticals plc. Previously, David worked for GlaxoSmithKline plc, which he joined in 1988 as a graduate trainee and where he progressed through a number of senior roles in Finance, Information Management and Distribution to become Head of UK Finance and Senior Vice President of Financial Management in Research and Development He was also CFO for Strakan Pharmaceuticals, a privately owned biotechnology company.
David’s considerable industry experience and strong financial and management skills are important to the management of Acambis’ continued growth. He oversees the Finance function and is responsible for the business’ financial planning.
He is a member of the Group Executive Committee.
|
Dr Phil L'Huillier,
Director, Business Management,
Cancer Research Technology Limited
|
 Mr Chris Mason,
Regenerative Medicine Bioproessing Group,
University College London
Chris is at the forefront of the emerging field of regenerative medicine bioprocessing plus is involved in a number of committees, working groups and initiatives related to both the academic and commercial advancement of stem cells and tissue engineering. Originally graduating from Imperial College (Molecular Biology) and St. Thomas’s Hospital Medical School (Medicine) and then specialising in surgery - Fellow of the Royal College of Surgeons. In addition, Chris has a PhD in Biochemical Engineering (UCL), leads the Regenerative Medicine Bioprocess Group at UCL and has broad range of expertise in industrial consultancy. Furthermore, Chris has over ten years experience at boardroom level of running technology companies and is co-organiser of the London Regenerative Medicine Network.
|
Melanie McCullagh,
Senior Business Development Manager,
Antisoma
|
 Dr Amanda McMurray,
Commercialisation Manager,
Cenamps
Dr Amanda McMurray is Cenamps’ Commercialisation Manager engaged on innovation exploitation activities for SMEs, emerging and start-up business and Universities in the North East of England.
Fundamental to her work is the alignment of research activities with specific industry needs with the aim always of developing customers’ strategic capabilities and strengthening their competitive position.
Amanda has extensive experience of bringing together the two worlds of science and business and combines strategic business experience with scientific and technical background. She has over 15 years of experience of innovation and new technology development and commercialization in life sciences and biotechnology working with industry and academia in the UK, Europe and US.
She worked previously with PA Consulting Group, where she specialized in Life Sciences, Genomics and Biotechnology, BBT Ltd, independently as a Consultant to clients including a global biotechnology company, and as Development Manager for the Sanger Centre (now Sanger Institute).
|
 Michael O’Sullivan,
Managing Director,
Plexus Ventures
Michael O’Sullivan is Managing Director of Plexus Ventures based in its London office. Plexus Ventures specialises in providing Strategic Advice and Business Development services to the Pharmaceutical industry.
Prior to joining Plexus Ventures, Mr. O’Sullivan served as Chief Financial Officer of Ethical Holdings plc for four years, where in addition to the financial affairs of the company, his responsibilities included corporate and business development activities. Previously, Mr O’Sullivan spent 21 years at SmithKline Beecham where his duties included Vice President of Finance – Europe for Consumer Products; Vice President, Strategic Planning for Worldwide Pharmaceuticals; and Controller, Southern Europe Pharmaceuticals. For a number of years, Mr. O’Sullivan was responsible for SB’s pricing and transfer pricing policies.
|
Andrew Pasternak,
Director,
Mercer Management Consulting
|
 Mr Daniel Pavin,
Partner,
Taylor Wessing
Daniel Pavin is a partner in the Intellectual Property Department in Taylor Wessing’s London office. He has a broad practice focused on life sciences and healthcare, technology and IT sectors, and advises on both non-contentious and contentious matters. Key areas include commercial agreements, intellectual property aspects of mergers, acquisitions and investments, contract disputes in life sciences and healthcare, technology and IT sectors and data protection and privacy.
|
 Christoph Sachsenmaier,
Head of Business Development Clinical Solutions,
Epigenomics
Christoph joined Epigenomics (Berlin, Germany) in 2004 and heads the Business Development efforts at Epigenomics' Clinical Solutions unit since beginning of 2006. Before, Christoph spent 4 years at ProQinase GmbH (Freiburg, Germany) leading all Business Development, Marketing and Sales activities in the field of protein kinase research. Before joining ProQinase, Christoph worked as a scientific group leader at the Tumor Biology Center Freiburg which he joined in 1999 after spending almost 4 years at the Fred Hutchinson Cancer Research Center (Seattle, USA) as a postdoctoral fellow. Christoph obtained his PhD in Biology from the University of Innsbruck, Austria.
|
 Dr Supti Sarkar,
Technology Analyst,
London Technology Network
Dr Supti Sarkar works as a Technology Analyst at the London Technology Network (LTN). Supti specialises in the life sciences sector concentrating on technologies within the Pharma, Biotech and Food Industries. Prior to joining LTN, Supti worked in Supply Chain Management at Unilever, Supti worked as part of the European Team at Unilever to enable cost saving measures to be introduced across the supply chain. Since joining LTN in September 2005, Supti has worked to help companies across the world engage effectively with academics in the South East of England, in order to help them address their technology needs. Supti holds a degree and Ph.D in Biochemical Engineering from University College London.
|
 Dr Richard Seabrook,
Head of Business Development, Technology Transfer Division,
The Wellcome Trust
Richard Seabrook PhD, MBA, is a founding member of the Technology Transfer Division, Wellcome Trust, where he is Head of Business Development. He is also technology transfer advisor to the Wellcome Trust Sanger Institute and Genome Research Limited. Richard has extensive experience with early-stage funding of life science technologies, investment and licensing transactions, intellectual property management, board, SAB and government agency advisory roles.
|
 Dr Jean-Denis Shu,
Chairman and Chief Executive Officer,
Bio-Crown Technology Ltd
Formerly the Regional Director of Far East & North Pacific for Chiron Vaccines, Dr. Shu is widely recognized as a vaccine expert in China. He has got extensive experiences in business start-ups and general management in vaccine industry and strong resources and network in North Asia. His ten-year career in vaccine field also includes General Delegate China for Aventis Pasteur, based in Beijing, China, and Medical and Regulatory Affairs Manager for Pasteur Merieux Connaught, based in Lyon, France. Dr. Shu was the author of several articles and books on vaccines.
A French citizen born in Shanghai, Dr. Shu is bi-cultural and tri-lingual (English, French and Chinese). He earned a Certificate of Finance and Accounting from Wharton School in Philadelphia, a MBA from the European School of Management (ESCP-EAP) in Paris, a Diploma of medical specialization from the Medical and Pharmacy College of Besancon in France, and a Medical Degree, B. Med. from Shanghai Second Medical University in China. Dr Shu had spent five years as Foreign Physician in French hospitals, before having joined vaccine industry.
|
 Dr Malcolm Skingle,
Director, Academic Liaison, Worldwide Business Development,
Glaxosmithkline
Malcolm Skingle has BSc in Pharmacology/Biochemistry and a PhD in Neuropharmacology. He has worked in the pharmaceutical industry for more than 30 years and has gained a wide breadth of experience in the management of research activities. Part of his former role as a research leader in a Neuropharmacology department involved co-supervising collaborations with academics in the UK, Europe and USA. He has more than 60 publications including articles on the interface between industry and academia. For more than a decade he has managed Academic Liaison at GSK and has staff in Stevenage, Research Triangle Park and Philadelphia. This role involves close liaison with several groups outside the Company e.g. Government Departments, Research and Funding Councils, Small Biotechnology Companies and other science-driven organisations. He sits on many external bodies including the BBSRC Strategy Board, the East of England RDA Science and Industry Council, the CBI academic liaison group and several UK University Department advisory groups. He chairs several groups including the BBSRC Bioscience for Industry Panel, the Diamond (Synchotron) Industrial Advisory Board, the Inner Core Lambert working group on boilerplate agreements and the ABPI group working on academic liaison.
|
 Ben Tan,
Head of Business Development and Licensing,
Speedel
Ben T.G. Tan joined Speedel Pharma Ltd in 2001 as Head of Business Development & Licensing. He has an M.Sc. in medical biology (Free University, Amsterdam, The Netherlands) and gained extensive marketing and sales experience during his 11 years at Roche Netherlands (1986-1993) and at Roche Headquarters in Switzerland (1994-1997). Ben Tan served as head of the licensing department at Organon/Akzo Nobel in The Netherlands(1997-2000) and as executive VP Business at Devgen N.V in Belgium (2000-2001).
|
 Dr Brian Tempest,
Chief Mentor & Chairman,
Ranbaxy
Dr. Brian Tempest has worked in the pharma industry for the last 36 years. During this time he has worked for several pharma majors, including Glaxo & Searle, around the world and joined Ranbaxy 12 years ago. During this period Ranbaxy has transformed from a small company focused on the India domestic market, to a top 10 global generic company. Dr. Tempest lives in New Delhi, India and has been President, Managing Director & Chief Executive Officer and is presently the Chief Mentor & Executive Vice Chairman of the Board. Dr. Tempest is scheduled to retire from Ranbaxy in 2007, when he reaches 60. Dr. Tempest is one of a few westerners to hold a leadership position in an Indian blue chip MNC, and has a unusual insight into India.
Dr Tempest is also a Honorary Professor of the Management School at Lancaster University, UK, and he sits on the Editorial Board of the Journal of Generic Medicines.
|
Dr Iain Thomas,
Head of Life Sciences,
Cambridge Enterprise
|
Dr Geraldine Venthoye,
Head of Business Unit - Inhalation and Aerosols,
SkyePharma AG
|
 Dr Eric von Hofe,
Vice President,
Generex
Dr. Eric von Hofe has been a Vice President at Generex and President of Antigen Express, a wholly-owned subsidiary of Generex Biotechnologies, and since April 2005. He joined Antigen Express in November 2003 as Vice President of Technology Development. He has extensive experience with technology development projects, including his previous position at Millennium Pharmaceuticals as Program Director for Target Validation. Prior to that, Dr. von Hofe was Director, New Targets at Hybridon, Inc., where he coordinated in-house and collaborative research that critically validated gene targets for novel antisense medicines. Dr. von Hofe also held the position of Assistant Professor of Pharmacology at the University of Massachusetts Medical School. He received his Ph.D. from the University of Southern California in Experimental Pathology and was a postdoctoral fellow at both the University of Zurich and Harvard School of Public Health. His work has been published in thirty-four articles in peer-reviewed journals, and he has been an inventor on four patents.
|
Dr Alan Warrander,
Wood Mackenzie
|
 Dr Andrew Wood,
Executive Director, Global External Research and Development,
Eli Lilly
Andrew Wood qualified in medicine at Oxford University. He joined Eli Lilly & Co in 1991, following 10 years in academic medicine. He has been involved in many aspects of drug development, with particular emphasis on Neuroscience compounds, and has led both clinical and preclinical research activities in UK, Belgium and Japan. He is currently responsible for the European regional component of Lilly’s Global External R&D function.
|
Amanda Wooding,
Director of Business Development,
Acambis
|
|
|
|
